NOF EUROPE
   
Welcome
Image Sample

 

 

Welcome to our web site! On this site, we would like to introduce the outline of our business highlighting several areas of importance. NOF EUROPE (BELGIUM) NV is a subsidiary of NOF CORPORATION in Japan and was established in 2002. We have been serving to our customers  in European countries with a wide variety of products of specialty chemicals. NOF CORPORATION is comprised of such divisions as Oleo & Speciality Chemicals , Functional Chemicals & Polymers, Explosives & Propulsion, Functional Foods, Life Science Products, DDS Development,Functional Films, Electronic Materials and Anti-Corrosion. We are  highly specialized in handling excipients for pharmaceutical and specialty chemicals in Europe. The uses of excipients for pharmaceutical offered by our DDS Development Division have been increasing rapidly in Europe and in the U.S. We introduce on this website key products of DDS Development Division, such as Activated PEG (Polyethylenglycol Derivatives), PEGylation, Phospholipids, Liposomes, Ultra-pureity Polysorbate 80, Highly-purified low-molecular weight PEG, Cholesterol Pulluan, MPC Polymers, Novel Solubilizeres, Highly-purified Chitosans, Biocompatible PEG Anchors for cell membrane and LIPONIZER for liposome production. We appreciate it very much if you could give us your comments or inquiries about our products. E-mail us at: info@nofeurope.com


 









What's New
DDS

2010/07/26 Program for Liposome Conference in Vancouver, Aug 4-8, 2010
PDF

2010/07/08 NOF presents at Liposome Conference in Vancouver, Aug 4-8, 2010

2010/06/30
NOF release New Activated PEG

2010/05/21 NOF AMERICA CORPORATION opened a new office in California

On May 7, NOF AMERICA CORPORATION, a wholly owned subsidiary of NOF,
opened a new office in California to further enhance its sales
activities in the North American market
Post Address: 2102 Business Center Drive, Suite 130 Irvine, CA 92612, USA

2010/03/11 NOF partners with ENZON on PEG derivatives PDF

2010/01/07 NOF signs Exclusive Licensing Agreement on Novel Carrier for Gene Delivery PDF